Want to see PBLA full AI Analyst Report?
PBLA Stock Chart & Stats
$0.01
<$0.01(1.80%)
At close: 4:00 PM EST
$0.01
<$0.01(1.80%)
Day’s Range― - ―
52-Week Range<$0.01 - $2.50
Previous CloseN/A
Volume4.43K
Average Volume (3M)4.36K
Market Cap
$53.89K
Enterprise Value$2.67M
Total Cash (Recent Filing)$142.00K
Total Debt (Recent Filing)$6.39M
Price to Earnings (P/E)―
Beta1538.65
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,854,831
10 Day Avg. Volume549
30 Day Avg. Volume4,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-12.14
Price to Sales (P/S)0.00
P/FCF Ratio-2.27
Enterprise Value/Market Cap49.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.09
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic InvestmentThis investment demonstrates confidence in Panbela's approach and provides crucial financial support, enabling continued R&D and clinical trials.
Clinical Trial ProgressProgress in the ASPIRE trial suggests potential improvements in patient outcomes, enhancing Panbela's competitive position in cancer treatment.
FDA ApprovalFDA approval of eflornithine validates Panbela's polyamine-focused approach, potentially opening new revenue streams and enhancing market credibility.
Bears Say
Financial InstabilityOngoing financial losses highlight significant operational challenges and reliance on external funding, which may impact long-term viability.
Cash Flow ConcernsLow cash reserves indicate potential liquidity issues, necessitating continuous external funding to sustain operations and strategic initiatives.
Negative EquityNegative equity reflects financial instability, posing a risk of insolvency and limiting the company's ability to secure favorable financing terms.
Panbela Therapeutics News
PBLA FAQ
What was Panbela Therapeutics’s price range in the past 12 months?
Panbela Therapeutics lowest stock price was <$0.01 and its highest was $2.50 in the past 12 months.
What is Panbela Therapeutics’s market cap?
Panbela Therapeutics’s market cap is $53.89K.
When is Panbela Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Panbela Therapeutics’s earnings last quarter?
Currently, no data Available
Is Panbela Therapeutics overvalued?
According to Wall Street analysts Panbela Therapeutics’s price is currently Overvalued.
Does Panbela Therapeutics pay dividends?
Panbela Therapeutics does not currently pay dividends.
What is Panbela Therapeutics’s EPS estimate?
Panbela Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panbela Therapeutics have?
Panbela Therapeutics has 4,854,831 shares outstanding.
What happened to Panbela Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Panbela Therapeutics?
Currently, no hedge funds are holding shares in PBLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panbela Therapeutics
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.